CG Oncology, Inc.
CGON
$64.26
-$0.19-0.30%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.32M | 1.67M | -- | 52.00K | 456.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.32M | 1.67M | -- | 52.00K | 456.00K |
| Cost of Revenue | 33.03M | 29.46M | 31.33M | 27.47M | 26.80M |
| Gross Profit | -30.71M | -27.80M | -31.33M | -27.42M | -26.34M |
| SG&A Expenses | 17.99M | 23.33M | 17.41M | 14.79M | 11.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.02M | 52.80M | 48.74M | 42.26M | 38.51M |
| Operating Income | -48.70M | -51.13M | -48.74M | -42.20M | -38.05M |
| Income Before Tax | -41.31M | -43.81M | -41.43M | -34.45M | -31.80M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -41.31M | -43.81M | -41.43M | -34.45M | -31.80M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.31M | -43.81M | -41.43M | -34.45M | -31.80M |
| EBIT | -48.70M | -51.13M | -48.74M | -42.20M | -38.05M |
| EBITDA | -47.85M | -50.71M | -48.59M | -42.18M | -38.05M |
| EPS Basic | -0.52 | -0.57 | -0.54 | -0.45 | -0.46 |
| Normalized Basic EPS | -0.32 | -0.36 | -0.34 | -0.28 | -0.29 |
| EPS Diluted | -0.52 | -0.57 | -0.54 | -0.45 | -0.46 |
| Normalized Diluted EPS | -0.32 | -0.36 | -0.34 | -0.28 | -0.29 |
| Average Basic Shares Outstanding | 80.06M | 76.73M | 76.23M | 76.19M | 69.05M |
| Average Diluted Shares Outstanding | 80.06M | 76.73M | 76.23M | 76.19M | 69.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |